scholarly journals Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler

2015 ◽  
Vol 28 (3) ◽  
pp. 189-201 ◽  
Author(s):  
P. Worth Longest ◽  
Laleh Golshahi ◽  
Srinivas R.B. Behara ◽  
Geng Tian ◽  
Dale R. Farkas ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder

Influence of Mouthpiece Geometry on the Aerosol Delivery Performance of a Dry Powder Inhaler

2007 ◽  
Vol 24 (8) ◽  
pp. 1450-1456 ◽  
Author(s):  
Matthew S. Coates ◽  
Hak-Kim Chan ◽  
David F. Fletcher ◽  
Herbert Chiou
Keyword(s):  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder ◽  
Delivery Performance

scholarly journals The Acoustic Features of Inhalation can be Used to Quantify Aerosol Delivery from a Diskus™ Dry Powder Inhaler

2014 ◽  
Vol 31 (10) ◽  
pp. 2735-2747 ◽  
Author(s):  
Jansen N. Seheult ◽  
Peter O’Connell ◽  
Kee Chun Tee ◽  
Tariq Bholah ◽  
Hasan Al Bannai ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Acoustic Features ◽  
Aerosol Delivery ◽  
Dry Powder

Importance of Powder Residence Time for the Aerosol Delivery Performance of a Commercial Dry Powder Inhaler Aerolizer®

2012 ◽  
Vol 25 (5) ◽  
pp. 265-279 ◽  
Author(s):  
Liqun Jiang ◽  
Yue Tang ◽  
Hongjiu Zhang ◽  
Xifeng Lu ◽  
Xijing Chen ◽  
...  
Keyword(s):  
Residence Time ◽  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder ◽  
Delivery Performance

AEROSOL DELIVERY FROM AN ACTIVE EMISSION MULTI-SINGLE DOSE DRY POWDER INHALER

1997 ◽  
Vol 15 (1) ◽  
pp. 51-63 ◽  
Author(s):  
N. M. CONCESSIO ◽  
R. JÄGER-WALDAU ◽  
A. J. HICKEY
Keyword(s):  
Single Dose ◽  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder

A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness

2021 ◽  
Vol 42 (1) ◽  
pp. 30-35 ◽  
Author(s):  
Donald P. Tashkin ◽  
Arkady Koltun ◽  
Róisín Wallace
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Fluticasone Propionate ◽  
Healthy Volunteers ◽  
Pulmonary Disease ◽  
Dry Powder Inhaler ◽  
Chemical Degradation ◽  
Chronic Obstructive ◽  
Dry Powder ◽  
Obstructive Pulmonary Disease ◽  
Flow Rates

Background: A generic combination of fluticasone propionate and salmeterol xinafoate inhalation powder in a premetered, multidose, nonreusable inhaler was recently approved. Objective: To assess the performance of the generic device. Methods: Findings from three studies with regard to device usability, function, and robustness were reviewed. Results: In a study to assess device function in patients and healthy volunteers, the generic device was successfully used by patients with asthma and chronic obstructive pulmonary disease who were either dry powder inhaler users or dry powder inhaler‐naive, even though they were not trained beyond being provided the instructions for use. In a study to measure inhaled flow rates generated by patients and healthy volunteers, the generic device consistently simulated the delivery of a full dose of drug, even to patients with severe respiratory disease and reduced inspiratory flow rates. Although the generic device had a slightly higher airflow resistance, this study demonstrated that this difference did not result in any clinically meaningful differences in terms of drug delivery. Pressure drop, a key parameter that drives the fluidization and aerosolization of the powder dose, was found to be comparable between the devices. In an open-label study, the generic device met all U.S. Food and Drug Administration specifications for device robustness after 21.5 days of twice-daily dosing via oral inhalation among 111 participants with asthma or chronic obstructive pulmonary disease. All inhalers tested demonstrated conformity with a pharmacopeia with respect to key quality parameters (assay, delivered dose uniformity, aerodynamic size distribution). There was no evidence of chemical degradation of the active ingredients, nor of microbial or water ingress into the powder, as a result of inhaler use.

Sign in / Sign up

Export Citation Format

Share Document